Top Industry Leaders in the Dravet Syndrome Market
Latest Dravet Syndrome Companies Updates
Stoke Therapeutics (NASDAQ: STOK): Presented positive data from their Phase 2 open-label extension study of STK-001, an antisense oligonucleotide therapy targeting the SCN1A gene mutation responsible for Dravet Syndrome.
Eisai Inc.: Initiated a Phase 3 clinical trial called Momentum I to study the efficacy of lorcaserin as an adjuctive (add-on) treatment in Dravet Syndrome to reduce seizure frequency.
Encoded Therapeutics: Collaborating with Cook Children's Medical Center on a non-interventional study to identify potential biomarkers for Dravet Syndrome using GABA levels in the blood.
Zogenix Inc.: Partnered with the DSF to provide educational grants to healthcare professionals on the use of Fintepla (fenfluramine) for Dravet Syndrome treatment.
List of Dravet Syndrome Key companies in the market:
- Biocodex
- Biscayne Neurotherapeutics
- Cyberonics
- Epygenix Therapeutics
- GW Pharmaceuticals
- INSYS THERAPEUTICS
- OPKO Health Inc.
- Ovid Therapeutics
- PTC Therapeutics
